These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19297157)

  • 1. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
    Yamamoto T; Shibata N; Sukeguchi D; Takashima M; Nakamura S; Toru T; Matsunaga N; Hara H; Tanaka M; Obata T; Sasaki T
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3973-6. PubMed ID: 19297157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzymatic resolution and evaluation of enantiomers of cis-5'-hydroxythalidomide.
    Yamamoto T; Shibata N; Takashima M; Nakamura S; Toru T; Matsunaga N; Hara H
    Org Biomol Chem; 2008 May; 6(9):1540-3. PubMed ID: 18421383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.
    Tokunaga E; Akiyama H; Soloshonok VA; Inoue Y; Hara H; Shibata N
    PLoS One; 2017; 12(8):e0182152. PubMed ID: 28763493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis.
    Shah JH; Swartz GM; Papathanassiu AE; Treston AM; Fogler WE; Madsen JW; Green SJ
    J Med Chem; 1999 Aug; 42(16):3014-7. PubMed ID: 10447943
    [No Abstract]   [Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor.
    Hu S; Yuan L; Yan H; Li Z
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4075-4081. PubMed ID: 28757066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity.
    Nakamura T; Noguchi T; Kobayashi H; Miyachi H; Hashimoto Y
    Chem Pharm Bull (Tokyo); 2006 Dec; 54(12):1709-14. PubMed ID: 17139107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concise asymmetric synthesis of configurationally stable 4-trifluoromethyl thalidomide.
    Soloshonok VA; Yamada T; Sakaguchi K; Ohfune Y
    Future Med Chem; 2009 Aug; 1(5):897-908. PubMed ID: 21426088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural development of biological response modifiers based on thalidomide.
    Hashimoto Y
    Bioorg Med Chem; 2002 Mar; 10(3):461-79. PubMed ID: 11814832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of thalidomide.
    Eriksson T; Björkman S; Höglund P
    Eur J Clin Pharmacol; 2001 Aug; 57(5):365-76. PubMed ID: 11599654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application.
    Contino-Pépin C; Parat A; Périno S; Lenoir C; Vidal M; Galons H; Karlik S; Pucci B
    Bioorg Med Chem Lett; 2009 Feb; 19(3):878-81. PubMed ID: 19103485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer.
    Capitosti SM; Hansen TP; Brown ML
    Bioorg Med Chem; 2004 Jan; 12(2):327-36. PubMed ID: 14723953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Search for new anti-angiogenic agents with structural analogy with thalidomide].
    Vidal M; Gasse C; Garbay C; Galons H
    Ann Pharm Fr; 2005 Jan; 63(1):85-9. PubMed ID: 15803105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and configurational stability of (S)- and (R)-deuteriothalidomides.
    Yamamoto T; Tokunaga E; Nakamura S; Shibata N; Toru T
    Chem Pharm Bull (Tokyo); 2010 Jan; 58(1):110-2. PubMed ID: 20045977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis inhibitors derived from thalidomide.
    Noguchi T; Fujimoto H; Sano H; Miyajima A; Miyachi H; Hashimoto Y
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5509-13. PubMed ID: 16183272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Synthesis of 1,3-dihydro-1,3-dioxo-2H-isoindole derivatives].
    Yang Y; Xiang D; Guo J; Zheng YS; Ye B; Yang JL; Cheng L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 39(4):645-7. PubMed ID: 18798515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
    Luzzio FA; Mayorov AV; Ng SS; Kruger EA; Figg WD
    J Med Chem; 2003 Aug; 46(18):3793-9. PubMed ID: 12930142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed?
    Ley AM; Chau CH; Figg WD
    Cancer Biol Ther; 2015; 16(1):19-20. PubMed ID: 25692618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of in vivo anticancer and antiangiogenic potential of thalidomide derivatives.
    da Costa PM; da Costa MP; Carvalho AA; Cavalcanti SM; de Oliveira Cardoso MV; de Oliveira Filho GB; de Araújo Viana D; Fechine-Jamacaru FV; Leite AC; de Moraes MO; Pessoa C; Ferreira PM
    Chem Biol Interact; 2015 Sep; 239():174-83. PubMed ID: 26134001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid-phase synthesis of thalidomide and its analogues.
    Xiao Z; Schaefer K; Firestine S; Li PK
    J Comb Chem; 2002; 4(2):149-53. PubMed ID: 11886289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives.
    Sievers J; Voget R; Lu F; Garchitorena KM; Ng YLD; Chau CH; Steinebach C; Figg WD; Krönke J; Gütschow M
    Bioorg Med Chem Lett; 2024 Sep; 110():129858. PubMed ID: 38917956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.